Top news of the day from across the health care landscape.
A new study showed that the diabetes drug canagliflozin (Invokana, Janssen) may help prevent or slow kidney disease, The Associated Press reported. According to the article, the researchers evaluated 13,000 individuals with type 2 diabetes and chronic kidney disease who were given either canagliflozin or a placebo. Overall, those who received canagliflozin had a 30% lower risk of kidney failure, need for dialysis, need for a kidney transplant, death from kidney- or heart-related causes, or other signs of kidney failure, the article reported.
Approximately half of patients with cancer experience symptoms of insomnia, Reuters reported. According to the article, a recent study examined data on 405 patients with cancer and completed 2 assessments of insomnia severity, once when they joined the study and again 12 months later. At the start of the study, 49% of patients had insomnia symptoms and 64% of patients who started out with insomnia were still experiencing symptoms after 1 year, the article reported.
Data revealed that an experimental Ebola vaccine being used to contain the outbreak in the Democratic Republic of the Congo is protective 97.5% of the time, STAT reported. According to the article, of more than 90,000 individuals who were vaccinated, only 71 went on to develop Ebola and 56 of those individuals developed symptoms fewer than 10 days after being vaccinated. Additionally, only 15 individuals developed Ebola more than 10 days after being vaccinated, the article reported.